ArchiMed's Bomi bolts on Logifarma

The vendors are Armonia (the holding company of the Paradisi family), Andrea Nardo and Roberto Pucci.

ArchiMed told Unquote that it intends to continue to pursue a buy-and-build strategy aimed at consolidating and strengthening Bomi's market position. The GP said further deals are already in the pipeline for Bomi.

Established in 1985 and based in Vaprio d'Adda, near Milan, Bomi specialises in transport, warehousing and supply chain management for healthcare companies ranging from pharmaceutical and medical equipment manufacturers to hospitals, testing laboratories and outpatient services. The business operates in 20 countries across Europe, the Americas and Asia, and generated EBITDA of around €12m from revenues of €125m.

ArchiMed acquired Bomi in a €70m take-private in May 2019, de-listing the company from the Milan stock exchange. The GP invested in Bomi via its mid-market fund, Med Platform I, which was launched in June 2018 with a target of €800m and held a €530m first close in October 2018.

Company
Established in 1997 and based in Pomezia, near Rome, Logifarma specialsies in logistics for the pharmaceutical industry. The company generated revenues of around €6m in 2019.

People
ArchiMed – Stefano Camurri (head of southern Europe).
Bomi – Marco Ruini (CEO).
Logifarma – Giuseppe Paradisi (CEO).

Advisers
Acquirer – Simmons & Simmons (legal).
Company – Heussen (legal, tax).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• Southern Europe
• Industrials
• Archimed
• Italy
• Build-up
• Buy-and-build